SEC Form 4 · accession 0001114220-18-000062
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven C Gilman
Director
Period of report
Jun 11, 2018
Accepted (ET)
Jun 12, 2018 · 4:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 11, 2018 | S | 1,334 | $5.12 | D | 17,333 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sale of a total of 1,334 shares of common stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2017.
- F2Includes 9,999 shares of restricted stock.